Amy Thomas

Medicine & Life Sciences

1. Cancer Vaccines 100%
2. Pancreatic Neoplasms 78%
3. T-Lymphocytes 76%
4. mesothelin 65%
5. Cross-Priming 58%
6. Neoplasm Antigens 54%
7. Granulocyte-Macrophage Colony-Stimulating Factor 50%
8. Lentivirus 48%
9. Allogeneic Cells 44%
10. Antigens 43%
11. Antigen-Presenting Cells 43%
12. Renal Cell Carcinoma 39%
13. Neoplasms 35%
14. Delayed Hypersensitivity 35%
15. Cytokines 25%
16. Gene Expression 24%
17. HLA-A24 Antigen 22%
18. pancreas-specific antigen 22%
19. Kidney 22%
20. HLA-A Antigens 21%
21. Vaccination 20%
22. Genes 20%
23. Tumor-Associated Carbohydrate Antigens 18%
24. HLA-A2 Antigen 18%
25. Transgenes 18%
26. HIV-1 15%
27. Lymphocytes 15%
28. Cell Line 12%
29. Immunotherapy 11%
30. Green Fluorescent Proteins 9%
31. Vaccines 9%
32. Clone Cells 9%
33. Needles 9%
34. HLA-A*02:01 antigen 8%
35. Histocompatibility Antigens Class I 8%
36. HLA-B Antigens 7%
37. Antigen Presentation 7%
38. Clinical Trials, Phase I 7%
39. Radiotherapy 7%
40. Gene Expression Profiling 7%
41. Major Histocompatibility Complex 7%
42. Stem Cells 6%
43. Technology 6%
44. Viruses 6%
45. Drug Therapy 6%
46. Recurrence 5%
47. Epitopes 5%
48. Survival 5%
49. Tumor Burden 5%
50. Jurkat Cells 5%